JP2016006052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016006052A5 JP2016006052A5 JP2015134436A JP2015134436A JP2016006052A5 JP 2016006052 A5 JP2016006052 A5 JP 2016006052A5 JP 2015134436 A JP2015134436 A JP 2015134436A JP 2015134436 A JP2015134436 A JP 2015134436A JP 2016006052 A5 JP2016006052 A5 JP 2016006052A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- substitution
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 238000006467 substitution reaction Methods 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 12
- 206010054094 Tumour necrosis Diseases 0.000 claims 8
- 230000000259 anti-tumor effect Effects 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 150000008575 L-amino acids Chemical group 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005980 lung dysfunction Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110048505.1 | 2011-02-28 | ||
| CN201110048505 | 2011-02-28 | ||
| CN201210026698.5 | 2012-02-07 | ||
| CN201210026698.5A CN102675460B (zh) | 2011-02-28 | 2012-02-07 | 抗肿瘤坏死因子α的人源化抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516997A Division JP6054864B2 (ja) | 2011-02-28 | 2012-02-13 | 抗腫瘍壊死因子αヒト化抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016006052A JP2016006052A (ja) | 2016-01-14 |
| JP2016006052A5 true JP2016006052A5 (enExample) | 2016-11-04 |
Family
ID=46757361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516997A Expired - Fee Related JP6054864B2 (ja) | 2011-02-28 | 2012-02-13 | 抗腫瘍壊死因子αヒト化抗体 |
| JP2015134436A Pending JP2016006052A (ja) | 2011-02-28 | 2015-07-03 | 抗腫瘍壊死因子αヒト化抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516997A Expired - Fee Related JP6054864B2 (ja) | 2011-02-28 | 2012-02-13 | 抗腫瘍壊死因子αヒト化抗体 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2682405A4 (enExample) |
| JP (2) | JP6054864B2 (enExample) |
| KR (1) | KR101576559B1 (enExample) |
| CN (1) | CN102675460B (enExample) |
| AR (1) | AR085501A1 (enExample) |
| AU (1) | AU2012222738B2 (enExample) |
| BR (1) | BR112013021860A2 (enExample) |
| CA (1) | CA2827799C (enExample) |
| RU (1) | RU2549700C1 (enExample) |
| WO (1) | WO2012116595A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103217489B (zh) | 2013-01-15 | 2016-03-09 | 珠海市丽珠单抗生物技术有限公司 | 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法 |
| WO2015190439A1 (ja) * | 2014-06-09 | 2015-12-17 | 株式会社カネカ | 抗体に結合する低分子化合物のスクリーニング方法 |
| CN109153718B (zh) * | 2016-03-17 | 2022-02-08 | 努玛治疗有限公司 | 抗TNFα抗体及其功能片段 |
| CN106279413A (zh) * | 2016-08-30 | 2017-01-04 | 苏州普罗达生物科技有限公司 | 抗肿瘤坏死因子抗体多肽及应用 |
| CN111153994B (zh) * | 2019-12-31 | 2021-10-15 | 武汉班科生物技术股份有限公司 | 人肿瘤坏死因子的人源单克隆抗体 |
| CN115819575B (zh) * | 2022-08-24 | 2023-06-27 | 武汉爱博泰克生物科技有限公司 | 针对人肿瘤坏死因子-α的单克隆抗体 |
| CN115710314B (zh) * | 2022-09-14 | 2025-10-28 | 江苏睿源生物技术有限公司 | 用于检测肿瘤坏死因子-α的抗体组合及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4818679A (en) | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| DE69233701T2 (de) | 1991-03-18 | 2008-04-10 | New York University | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| WO2003042247A2 (en) * | 2001-11-12 | 2003-05-22 | Merck Patent Gmbh | Modified anti-tnf alpha antibody |
| US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| CN1225479C (zh) * | 2002-12-23 | 2005-11-02 | 马菁 | 肿瘤坏死因子抗体,其制备方法以及药物组合物 |
| CN1255536C (zh) | 2003-11-13 | 2006-05-10 | 中国人民解放军第四军医大学 | 高亲和力抗肿瘤坏死因子单克隆抗体的可变区基因及其制备 |
| KR100772800B1 (ko) | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
| WO2006031370A2 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100971497B1 (ko) * | 2004-12-29 | 2010-07-21 | 주식회사유한양행 | 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체 |
| CN101177453B (zh) * | 2006-11-07 | 2010-09-29 | 旭华(上海)生物研发中心有限公司 | 抗人肿瘤坏死因子α的重组嵌合抗体 |
| KR20100053607A (ko) * | 2007-08-03 | 2010-05-20 | 패시트 바이오테크 코포레이션 | 항-tweak 수용체 항체의 치료 용도 |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| PL2242773T3 (pl) * | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
-
2012
- 2012-02-07 CN CN201210026698.5A patent/CN102675460B/zh active Active
- 2012-02-13 RU RU2013139480/10A patent/RU2549700C1/ru active IP Right Revival
- 2012-02-13 BR BR112013021860-6A patent/BR112013021860A2/pt not_active Application Discontinuation
- 2012-02-13 AU AU2012222738A patent/AU2012222738B2/en not_active Ceased
- 2012-02-13 CA CA2827799A patent/CA2827799C/en not_active Expired - Fee Related
- 2012-02-13 EP EP12752672.1A patent/EP2682405A4/en not_active Withdrawn
- 2012-02-13 WO PCT/CN2012/071079 patent/WO2012116595A1/zh not_active Ceased
- 2012-02-13 KR KR1020137025433A patent/KR101576559B1/ko not_active Expired - Fee Related
- 2012-02-13 JP JP2013516997A patent/JP6054864B2/ja not_active Expired - Fee Related
- 2012-02-28 AR ARP120100640A patent/AR085501A1/es unknown
-
2015
- 2015-07-03 JP JP2015134436A patent/JP2016006052A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016006052A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| JP2016063812A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2017113028A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| IL295534A (en) | Improved immunoglobulin variable domains | |
| JP2019522961A5 (enExample) | ||
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| JP2016521688A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2016500673A5 (enExample) | ||
| JP2012254092A5 (enExample) | ||
| JP2017518258A5 (enExample) | ||
| JP2015509948A5 (enExample) | ||
| JP2014110810A5 (enExample) | ||
| JP2011504501A5 (enExample) | ||
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| JP2016524463A5 (enExample) | ||
| JP2013539354A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| CN109311974A (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
| JP2016511277A5 (enExample) |